Teva Pharmaceuticals Sustainability Profile
Teva Pharmaceuticals Industries Ltd., commonly known as Teva, is a global leader in the pharmaceutical industry, headquartered in Israel (IL). Founded in 1901, Teva has established a strong presence in over 60 countries, focusing on the development, production, and marketing of generic and specialty medicines. With a diverse portfolio that includes a wide range of therapeutic areas such as central nervous system disorders, oncology, and respiratory conditions, Teva is renowned for its commitment to accessibility and innovation. The company’s core products, including the widely used Copaxone and a robust selection of generic medications, set it apart in a competitive market. Teva's notable achievements include being one of the largest generic drug manufacturers globally, reflecting its significant market position and dedication to improving patient outcomes through affordable healthcare solutions.
DitchCarbon Score
How does Teva Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Teva Pharmaceuticals's score of 85 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Teva Pharmaceuticals's reported carbon emissions
In 2024, Teva Pharmaceuticals reported total greenhouse gas (GHG) emissions of approximately 4,406,116,000 kg CO2e, with emissions distributed across various scopes: 243,603,000 kg CO2e for Scope 1, 218,504,000 kg CO2e for Scope 2 (market-based), and a significant 4,066,116,000 kg CO2e for Scope 3. This represents a slight decrease from 2023, where total emissions were about 4,320,235,000 kg CO2e, with Scope 1 at 242,056,000 kg CO2e, Scope 2 at 239,069,000 kg CO2e, and Scope 3 at 4,320,235,000 kg CO2e. Teva has set ambitious targets to reduce its carbon footprint, aiming for a 25% reduction in absolute Scope 1 and 2 GHG emissions by 2025 and a 46% reduction by 2030, both compared to a 2019 baseline. Additionally, the company has committed to reducing absolute Scope 3 emissions by 25% by 2030 from a 2020 baseline. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to support global efforts to limit warming to 1.5°C. Teva has also announced its intention to achieve net zero emissions across its operations and value chain by 2045. This long-term commitment reflects the company's recognition of the urgent need for climate action within the pharmaceutical industry. Overall, Teva Pharmaceuticals is actively working towards significant emissions reductions while maintaining transparency in its climate commitments and progress.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Teva Pharmaceuticals's Industry?
How Carbon Intensive is Teva Pharmaceuticals's Location?
Teva Pharmaceuticals's Scope 3 Categories Breakdown
Teva Pharmaceuticals's Scope 3 emissions, which decreased by 6% last year and decreased by approximately 24% since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 61% of Scope 3 emissions.
Top Scope 3 Categories
Teva Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Teva Pharmaceuticals has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Teva Pharmaceuticals's sustainability data and climate commitments